Pivoting a product launch during the pandemic

Update: 2020-12-02

Description

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, high definition, protein biomarker profiles. Although their launch plans were disrupted by the pandemic, Bryan shares how Adarza responded to the challenge by utilizing Ziva for COVID-19 research.

Hosted on Acast. See acast.com/privacy for more information.

Comments

In Channel

Lighting the touch paper for next generation nucleic acid therapies

2023-05-0332:06

Realizing the patient-friendly future of clinical trials

2022-07-0523:02

How Patient Connect addresses unmet needs at the point of care

2022-04-1822:32

Social determinants: barriers to healthcare impacting racial and ethnic minorities

2022-02-1045:59

How Novo Ventures prioritized their investment strategy during the pandemic

2021-12-1325:50

How Healx uses AI to transform rare disease drug discovery

2021-12-0127:52

How the pandemic shifted Roche’s priorities and R&D investments

2021-11-1531:20

Optimizing patient-first clinical trials with advanced site intelligence

2021-11-0240:56

Showing the value of regulatory intelligence in pharma

2021-10-1131:32

Overcoming health inequity in the U.S. and the role of telehealth: Ideas and best practices from Cigna, Henry Ford Health System and the eHealth Initiative

2021-09-2136:46

Best practices for university - healthcare partnerships: Learnings from the Institute of Cancer Research

2021-08-1927:59

Best practices for university – healthcare partnerships: Learnings from Oxford

2021-07-3135:15